LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

13.55 -0.51

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.46

Máximo

13.8

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	5.243 66.845
Margem de lucro	163.843
Funcionários	1,780
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+51.62% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.5B
Abertura anterior	14.06
Fecho anterior	13.55

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mar. de 2026, 20:38 UTC

Ganhos

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 de mar. de 2026, 23:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

10 de mar. de 2026, 23:57 UTC

Conversa de Mercado

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 de mar. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 de mar. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 de mar. de 2026, 23:35 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 de mar. de 2026, 23:06 UTC

Ganhos

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 de mar. de 2026, 22:51 UTC

Notícias Principais

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 de mar. de 2026, 21:21 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 de mar. de 2026, 21:15 UTC

Ganhos

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 de mar. de 2026, 21:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 de mar. de 2026, 21:14 UTC

Ganhos

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 de mar. de 2026, 21:13 UTC

Ganhos

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 de mar. de 2026, 21:12 UTC

Ganhos

Franco-Nevada 4Q Rev $597.3M >FNV

10 de mar. de 2026, 21:12 UTC

Ganhos

Franco-Nevada 4Q EPS $1.90

10 de mar. de 2026, 20:57 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

10 de mar. de 2026, 20:44 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:34 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

10 de mar. de 2026, 20:34 UTC

Conversa de Mercado

Ganhos

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 de mar. de 2026, 20:23 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 de mar. de 2026, 20:16 UTC

Ganhos

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 de mar. de 2026, 20:14 UTC

Ganhos

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 de mar. de 2026, 20:14 UTC

Ganhos

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 de mar. de 2026, 20:13 UTC

Ganhos

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 de mar. de 2026, 20:12 UTC

Ganhos

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

51.62% parte superior

Previsão para 12 meses

Média 21 USD 51.62%

Máximo 21 USD

Mínimo 21 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.